Publication: Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia
Issued Date
2019-01-01
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-85073422518
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.12, (2019), 209-224
Suggested Citation
Thitipon Yaowaluk, Vorapun Senanarong, Chanin Limwongse, Rasda Boonprasert, Pornpimol Kijsanayotin Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia. Pharmacogenomics and Personalized Medicine. Vol.12, (2019), 209-224. doi:10.2147/PGPM.S211259 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50356
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia
Other Contributor(s)
Abstract
© 2019 Yaowaluk et al. Purpose: This study aims to evaluate the influence of genetic polymorphisms of CYP2D6, CYP3A5, ABCB1, and APOE genes and nongenetic factors on steady-state plasma concentrations (Cpss) of donepezil and therapeutic outcomes in Thai patients with Alzheimer’s disease (AD) and vascular dementia (VAD). Patients and methods: Eighty-five dementia patients who received donepezil for at least six months were recruited. CYP2D6, CYP3A5, ABCB1, and APOE polymorphisms were genotyped. Cpss of donepezil was measured. Association of genetic and non-genetic factors with Cpss and clinical outcomes of donepezil (cognitive function as measured by the Thai Mental State Examination score; TMSE) were determined by using univariate and multivariate analysis. Results: Both univariate and multiple linear regression analysis indicated that only CYP2D6*10 allele was associated with higher Cpss (p-value =0.029 and B =0.478, p-value =0.032, respectively) that might influence the clinical outcomes of donepezil. ie, TMSE (pvalue =0.010 and B =4.527, p-value =0.001) and δTMSE (p-value =0.023 and B =4.107, pvalue =0.002), especially in patients with AD. Interestingly, concomitant use of memantine was found to be associated with increased Cpss of donepezil (p-value =0.007 and B =0.511, p-value =0.014). Whereas, co-medication with antidepressant drugs attenuated clinical responses in patients with AD (TMSE: B =-2.719, p-value =0.013 and δTMSE: B = -2.348, p-value =0.028). Age was a significant predictor of donepezil response in VAD patients. No significant association of CYP3A5*3, ABCB1 3435C>T or ABCB1 1236C>T, and APOE e4 genotypes with Cpss or clinical outcomes of donepezil was found in this study. Conclusion: Our results suggests that CYP2D6*10 strongly influences Cpss and there is a trend toward better outcomes of donepezil in patients with AD. Nongenetic factors including concomitant drugs treatment might alter Cpss of donepezil or clinical outcomes.